Clinical Trials Directory

Trials / Completed

CompletedNCT01590173

Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles

Addition of Prednisolone and Heparin in Patients With Repeated Implantation Failures: a Prospective Clinical Study

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
86 (actual)
Sponsor
National and Kapodistrian University of Athens · Academic / Other
Sex
Female
Age
25 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The addition of heparin and prednisolone increases pregnancy outcome parameters in women undergoing In Vitro Fertilisation (IVF) with failed IVF cycles.

Conditions

Interventions

TypeNameDescription
DRUGPrednisolone and Heparin during COH for IVFLow Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
DRUGCOH for IVFBoth GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.

Timeline

Start date
2012-01-01
Primary completion
2016-07-01
Completion
2016-07-01
First posted
2012-05-02
Last updated
2016-07-19

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT01590173. Inclusion in this directory is not an endorsement.